Image: Wikimedia Commons
Blood clots blocked vessels in the brains of elderly Americans precisely as the Biden administration ramped up its final aggressive campaign for COVID-19 boosters. Internal systems flagged a statistically significant safety signal for ischemic stroke in those 65 and older who received the Pfizer bivalent shot. Officials responded by editing public language from “moderately elevated” to “slightly elevated” risk, issuing joint statements that still urged vaccination without pause or targeted precautions.
Documents released this week by Sen. Ron Johnson expose a pattern: surveillance systems detected harm, contractors investigated it quietly, and political pressure prioritized shots over transparency. For older Americans already at vascular risk, the stakes were immediate. The same regimen reached then-President Biden in his late 70s, coinciding with visible cognitive decline that ended his 2024 campaign. The government held evidence. It kept pushing the product.
Signal Detected and Repeatedly Confirmed
The CDC’s Vaccine Safety Datalink first identified the statistically significant ischemic stroke signal in seniors on November 27, 2022. Ischemic stroke cuts oxygen to brain tissue when a vessel blocks. The signal held through December 4, 11, 18, 25, and January 1, 2023, per records cited in Johnson’s letter to HHS Secretary Robert F. Kennedy Jr.
Empirical Bayesian data mining of VAERS data in early 2023 and again in March confirmed the finding. By February 7, 2023, officials had logged 226 stroke cases from VAERS dating to August 2022.
White House Edits and Public Reassurance
On January 11, 2023, CDC Director Rochelle Walensky received a draft communications plan with Biden White House changes. In the “Tough Questions and Answers” section, language shifted from describing the signal as “moderately elevated” to “slightly elevated.” Two days later, on January 13, FDA and CDC jointly acknowledged the signal in a statement but bolded twice that “no change is recommended in COVID-19 vaccination practice.” No formal health alert went out. No age-specific warnings followed. No booster pause occurred.
The “Stroke Project” and Incomplete Reviews
Behind closed doors, HHS contractor Lukos LLC launched the internal “Stroke Project.” A February 8, 2023 status report showed 110 cases assigned for review, with 67 percent completed. Officials relied on those partial reviews to back the January 13 public position of safety.
The project’s status flipped: reported completed in April 2023, reclassified as ongoing in May, and marked completed again in June. Its findings stayed unreleased. A CDC Morbidity and Mortality Weekly Report in April 2024 claimed “ongoing efforts to evaluate the [ischemic stroke] signal have not identified any clear and consistent evidence of a safety concern.” Yet a September 2024 MMWR noted a follow-up Vaccine Safety Datalink study still in progress. As late as September 19, 2025, a CDC presentation said further self-controlled case-series analysis continued.
Continued Promotion Despite Open Questions
Federal health officials kept recommending the booster for seniors through at least September 2025 while internal work persisted. Johnson’s letter requests more records and interviews with key figures, including Shimabukuro and FDA official David Menschik, who had earlier noted limits in data mining that could mask signals.
The paper trail reveals surveillance systems that worked, data runs that confirmed risk, and contractors who reviewed cases—yet public messaging never reflected the evidence. Instead, emphasis stayed on uptake.
For millions of elderly Americans exposed during this period, the human cost accumulated in silent vascular damage. The investigations dragged on while compliance remained the priority. Johnson’s release of nearly 2,000 pages of HHS records now places those choices under fresh scrutiny as oversight shifts.
